Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19

Abstract

Patients with COVID-19 have frequently been treated with convalescent plasma (ie, plasma from persons who have recovered from SARS-CoV-2 infection), but the clinical evidence of benefits or harms is limited.¹ Preliminary reports indicating that convalescent plasma is well tolerated with low risk of adverse events² led to Emergency Use Authorization in the US in August 2020.³ Despite the large number of clinical trials being conducted since the start of the pandemic, only a few have been published in peer-reviewed journals and some have posted preliminary results on preprint servers.